Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tui targets margin growth for airline unit, eyes new ships

(Sharecast News) - Travel company TUI said it was targeting a profit margin for its markets and airline unit of more than 3% in the medium term and confirmed it was in talks to build two new vessels for its Marella cruise fleet. The tour giant reiterated projections for operating profit to increase by 7% -10% year-on-year from almost €1.3bn last year, driven mainly by expectations for summer 2025 with a €30m phasing effect from Easter holidays shifting to the third quarter.

It is also looking targeting new revenue streams for the airline division, including selling more seat-only flights as well as offer more business-to-business opportunities.

"The goal is to strengthen the synergies between the various business areas, offer customers more products and significantly increase the number of customer contacts throughout the year," said chief Executive Sebastian Ebel ahead of the company's capital markets day in Madrid on Tuesday.

TUI also said that it is considering renewing some of its Marella cruise ship fleet to target the UK market and is in talks for two new ships to be built and available by 2031.

"Against the background of an ageing Marella Cruises fleet, we are currently exploring future growth options on how to position our highly profitable UK market leading business in a steadily growing market," Ebel said.

"We are in discussions with shipyards and we are currently considering ordering two vessels based on a design customised for the UK market. New-build slots are tentatively available from full-year 2031 onwards."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.